Table 4.

Background factors associated with the efficacy of vedolizumab

	P-value	OR	(95% CI)
Male sex	1.000	0.97	(0.17–5.59)
Pancolitis	0.683	0.64	(0.12–3.41)
Prior exposure to TNFα antagonists	0.691	1.37	(0.29–6.53)
Concomitant use of immunosuppressants	0.218	3.33	(0.59–18.89)
CAI (≥11)	0.356	0.28	(0.03–2.89)
Hb, g/dL (≥11.5)	0.014	15.0	(1.50–149)
CRP, mg/dL (≥0.3)	0.394	0.50	(0.10–2.46)
Alb, g/dL (≥3.5)	0.178	6.67	(0.67–66.5)
sMAdCAM-1, pg/mL (≥765)	0.004	17.3	(2.36–127)

OR: odds ratio

CI: confidence interval

CAI: Clinical Activity Index

Hb: hemoglobin

CRP: C-reactive protein

Alb: albumin

sMAdCAM-1: soluble mucosal addressin cell adhesion molecule 1